Table 2. A.
Summary of in vivo data for SG2285 in human tumor xenograft models LOX-IMVI (melanoma), advanced LS174T (colon), OVCAR-5 (ovarian) and SKOV-3 (ovarian)
| Model | Tumor Type |
Dose (batch) (mg/kg) |
Schedule (i.v.) |
Duration (days) |
%TGD1 | CR (TFS)2 |
|---|---|---|---|---|---|---|
| LOX-IMVI | Melanoma | 3 (1) | d × 1 | 68 | n/a | 7/7 (7/7) |
| LOX-IMVI | Melanoma | 3 (1) 1.5 (1) 0.75 (1) |
d × 1 d × 1 d × 1 |
86 86 86 |
n/a | 8/8 (8/8) 6/8 (6/8) 4/8 (4/8) |
| Advanced LS174T3 |
Colon | 4 (2) 1.5 (2) 0.8 (2) |
d × 1 q4d × 3 qd × 5 |
69 69 69 |
138 219 202 |
- - - |
| OVCAR-5 | Ovarian | 3 (1) | d x1 | 56 | 59 | - |
| SKOV-3 | Ovarian | 0.8 (2) 0.4 (2) 0.2 (2) 1.5 (2) 0.75 (2) 0.375 (2) |
qd × 5 qd × 5 qd × 5 q4d × 5 q4d × 5 q4d × 5 |
79 79 79 79 79 79 |
168 77 63 229 129 85 |
1/8 (1/8) 1/8 (1/8) - 1/8 (1/8)- 1/8 (1/8) |
| SKOV-3 | Ovarian | 0.1 (3) 0.25 (3) 0.5 (3) 0.2 (4) 0.5 (4) 1.0 (4) |
q4d × 3 q4d × 3 q4d × 3 q4d × 3 q4d × 3 q4d × 3 |
120 120 120 120 120 120 |
325 309 325 156 180 248 |
- - - 1/8 (1/8) - - |
1
%TGD = % tumour growth delay = [(T-C)/C] × 100
2
CR = total number of complete regressions, TFS = tumor free survivors (i.e. CRs at end of study)
3
Irinotecan (100 mg/kg i.p. qwk × 3) gave %TGD of 54 in this experiment (see figure 4B)